Publications by authors named "C Gaujoux-Viala"
Objectives: In axial spondyloarthritis (axSpA), patient-perceived quality of life/global functioning and health (GH) can be assessed using disease-specific [Assessment of SpondyloArthrit is international Society Health Index (ASAS-HI)] or generic [(3-level EuroQol 5 Dimensions (EQ-5D-3L)] scores. Our objectives were to explore the link between these scores and to define thresholds for good and poor GH.
Method: We conducted a post-hoc analysis of the cross-sectional ASAS-PerSpA study for patients fulfilling ASAS criteria for axSpA.
Article Synopsis
- The study aimed to compare the antibody response to SARS-CoV-2 in patients with inflammatory rheumatic diseases and healthy individuals.
- Researchers screened unvaccinated patients with conditions like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis in France, and matched them with seropositive healthcare workers as controls.
- Results showed no significant difference in antibody levels between both groups, with a trend indicating that patients with severe COVID-19 symptoms had higher antibody titres; treatments like glucocorticoids seemed linked to lower antibody responses.
Article Synopsis
- The French Society of Rheumatology updated its recommendations for managing rheumatoid arthritis (RA) based on the latest EULAR guidelines, involving a wide range of experts and patient representatives.
- The guidelines stress the importance of shared decision-making and comprehensive management for individuals with RA or those at risk, focusing on both drug and non-drug therapies.
- Additional emphasis is on the diagnosis and treatment of RA-related interstitial lung disease (RA-ILD), highlighting the need for collaboration between rheumatologists and pulmonologists for effective management.
Global health (GH) and health-related quality of life are patient priorities in axial spondyloarthritis (axSpA). Our objective was to assess the relative importance of disease-related factors including disease activity, and patient-related factors including comorbidities, to explain GH in axSpA. Post hoc cross-sectional analyses of 4 sets (COMOSPA, PERSPA, COMEDSPA, and DESIR) of patients fulfilling ASAS criteria for axSpA.
View Article and Find Full Text PDFObjectives: To compare the long-term outcomes of three phenotypes of axial SpA (axSpA).
Methods: Patients with a clinical diagnosis of axSpA from the DESIR cohort were grouped into three phenotypes at baseline: 'Pure axSpA' ('Axial'), 'axSpA with peripheral signs' ('IBP+Peripheral') and 'axSpA at risk' ('At risk') by latent class analysis. Clinical and imaging data were collected up to 5 years.